Navigation Links
Neurobiological Technologies Reports Third Quarter Fiscal 2009 Financial Results

igational drug which has recently completed a Phase 3 trial for brain swelling.

NOTE: Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including risks relating to our terminated clinical trials, our remaining contractual commitments, the success of our efforts to maximize the value of our cash and other assets for our shareholders, and levels of future operations and expenditures, as well as other risks detailed from time to time in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release and we undertake no obligation to update these forward-looking statements.

                               CONDENSED STATEMENTS OF OPERATIONS
                      (Unaudited - in thousands, except per share amounts)

                               Three months ended       Nine months ended
                                    March 31,                March 31,
                                2009        2008         2009        2008

         Royalty                1,505       2,161        5,590        6,245
         Technology sale
          and collaboration
          services              1,508       1,523        4,479        5,002

     Total revenues             3,013       3,684       10,069       11,247

         Research and
          development           1,857       5,945       17,701       18,822
         General and
          administrative        1,438       1,757        3,970        5,327

           Total expenses       3,295       7,702       21,671       24,149

     Operating los
SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Neurobiological Technologies Announces Appointment of William A. Fletcher as Acting CEO
2. Neurobiological Technologies Reports Second Quarter Financial Results
3. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
4. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
5. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
6. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
7. Neurobiological Technologies Reports Going Concern Qualification
8. Steven H. Kane Appointed as President and Chief Executive Officer of Patient Safety Technologies, Inc.
9. Global Med Technologies(R), Inc. to Report First Quarter Financial Results on Friday, May 15, 2009
10. EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results
11. Greenway Medical Technologies PrimeSuite Solution Provides OB/GYN Physicians With Instant Access to Labor and Delivery Information at Point-of-Care
Post Your Comments:
(Date:10/9/2015)... ... October 09, 2015 , ... Confidence Plus Insurance has just ... improvement initiative that involves working with a series of local charities throughout the ... Plus Insurance is the Gleason Park Electric Violin Ensemble (GPEVE). , GPEVE provides ...
(Date:10/9/2015)... ... October 09, 2015 , ... "As a nurse, I care for male patients ... have to wear large diapers or pads. We came up with this as a ... absorb urine leaking from the tip of the penis. This prevents stains from forming ...
(Date:10/9/2015)... Nedlands, WA, Australia (PRWEB) , ... October 09, ... ... be featured in an upcoming episode of Innovations with Ed Begley Jr., airing ... In this segment, Innovations will educate audiences on MMJ Phytotech Limited (MMJ) – ...
(Date:10/9/2015)... ... October 09, 2015 , ... Santa Rosa Consulting and ... as MD Anderson prepares to go-live on the Epic platform in March of 2016. ... 2016. Santa Rosa will execute the contract by supporting Scheduling Appointment Conversion and the ...
(Date:10/9/2015)... ... October 09, 2015 , ... Deadly, record-smashing rainfall has caused ... (CCCF) in Columbia, South Carolina. In response, the Foundation has established a national ... both short and long term. 100% of monies donated will go directly to ...
Breaking Medicine News(10 mins):
... Ireland to Start Up in Late 2008, WARSAW, ... ZMH), a leader in the orthopaedics industry, announced today,that ... a 100,000,square foot plant in Shannon, Ireland., "We ... to our global,network," said David Dvorak, Zimmer Holdings President ...
... WAYNE, Pa., Feb. 5 BioWizard, Inc.,( ... for the biomedical research community,announced today that as ... myBioWizard), a,unique personalization tool available at no cost ... researchers access to approximately,half a million new conference ...
... the savviest of gift-,givers, Valentine,s Day never fails to leave ... they love feel truly special. Of,course roses are the go-to ... job? Is a new HD TV the best way to ... of the reason why gift certificates sales were,second only to ...
... Continued Growth and Compliance, PASO ROBLES, Calif., ... and development of Enterprise Resource Planning (ERP) software, ... its comprehensive ERP,software, EnterpriseIQ. As Phase II continues ... does the level of visibility needed to,manage the ...
... shun these services, survey finds , , TUESDAY, Feb. 5 ... less often by American blacks than whites, and certain ... , An historical mistrust of the health-care system and ... care encourage many black Americans to avoid or delay ...
... CLARA, Calif., Feb. 5 Coherent, Inc.,(Pink Sheets: COHR), ... included in the company,s proxy for the annual meeting ... subject to election by,shareholders. The nominees include current directors ... Vij as well as first-time,nominees Susan James and Clifford ...
Cached Medicine News:
(Date:10/8/2015)... 2015 Johnson & Johnson (NYSE: JNJ ) ... trial in Sierra Leone of a ... Companies. Trial recruitment is underway, and the first volunteers have ... conducted of Janssen,s Ebola prime-boost vaccine regimen in a West ... Sierra Leone,s Kambia district, where some of ...
(Date:10/8/2015)... Oct. 8, 2015  Allergan plc (NYSE: AGN ... it will hold its R&D Day on November 4, ... – to 1:00 p.m. PT). The company will also ... at 9:00 a.m. ET (6:00 a.m. PT). ... --> Logo - ...
(Date:10/8/2015)... 08 2015 ... the "Natural Language Processing Market for ... Type (Rule-Based, Statistical, & Hybrid NLP Solutions), ... and Africa, Latin America) - Global Forecast ... --> ) has announced ...
Breaking Medicine Technology:
... DALLAS, Aug. 3 ACCESS PHARMACEUTICALS, INC. ... update today on its clinical development strategy for ProLindac , ... be active in many solid tumors in human clinical studies. Access has ... dose levels and regimens of ProLindac monotherapy in cancer patients, provide additional data ...
... Grammy-Award winning artist and long-time (PRODUCT)RED supporter John Legend ... for his August 13th, 2009 concert at Madison Square Garden in ... Gap stores in the New York tri-state area will include a ... reserved RED(ZONE) section for John Legend,s MSG show. Even better, with ...
Cached Medicine Technology:
... the ground-up with ergonomic concerns in mind ... adjustable observation tube on the market. Optional ... can adjust the microscope to suit their ... operator maintain an upright, comfortable posture, especially ...
... A standard laboratory microscope whose ... imagery combine to make it ... E400 is designed to fit ... the user to fit the ...
... When viewed through the enclosed ... provide a standard screening devise for ... tested. With normal stereo perception, the ... page in 3D. The test includes ...
... created to simplify stereopsis screening in children. It ... cylindrical gratings. Lang Stereotest II measures disparities: Moon ... 600 seconds of arc plus monocularly visible star. ... dots are smaller and less dense. This disparity ...
Medicine Products: